AHK-Cu for Health & Longevity
Evidence Review created on 10/25/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: Copper Tripeptide-3, AHK Copper Peptide, Alanyl-Histidyl-Lysine Copper, L-Alanyl-L-Histidyl-L-Lysine-Copper(II), Ala-His-Lys-Cu
Motivation
AHK-Cu (copper tripeptide-3) is a small synthetic molecule made of three amino acids, alanine, histidine and lysine, bound to a copper ion. It is a close chemical relative of a copper peptide that occurs naturally in human blood. Interest centers on the idea that it may signal hair follicles and skin cells to grow and repair, which has made it a common ingredient in scalp serums and in self-administered injection routines.
Its reputation rests largely on laboratory work with human hair follicles kept alive outside the body, together with older company animal studies of hair growth. In recent years it has been sold widely online as a “research” peptide next to its better-known relative and taken up by people who want to keep their hair, improve their skin and support tissue repair as part of a longevity routine.
This review examines what is and is not known about AHK-Cu: its proposed biology, the strength of evidence behind each claimed benefit, the risks of extra copper and of unregulated products, how it is used in practice, and how its effects can be tracked.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
The items below give a high-level overview of AHK-Cu and of the copper-peptide context in which it is used.
-
The effect of tripeptide-copper complex on human hair growth in vitro - Pyo et al., 2007
The only peer-reviewed primary study of AHK-Cu itself: very low concentrations lengthened cultured human hair follicles and multiplied dermal papilla cells (follicle-base cells that regulate hair growth).
-
Overview of Short Peptides for Hair Loss - Fan et al., 2026
Narrative review of short peptides that target dermal papilla cells; it places AHK-Cu beside GHK-Cu (glycyl-histidyl-lysine copper, a natural copper peptide in blood) and notes AHK-Cu’s poorly characterized signaling.
-
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data - Pickart & Margolina, 2018
Review of GHK-Cu, the tripeptide on which AHK-Cu was modeled, covering collagen and gene-expression effects; both peptides deliver copper that stimulates dermal fibroblast (collagen-making cell) and dermal papilla cell proliferation. Pickart’s company sells copper-peptide products.
-
Peptides: The Science, Uses & Safety – Dr. Abud Bakri - Andrew Huberman
Physician Abud Bakri discusses GHK-Cu, which shares AHK-Cu’s copper-delivering tripeptide action on skin and follicle cells, along with peptide sourcing and the gap between animal and human data.
Only four items are listed: no further content discusses AHK-Cu or its copper-peptide mechanism in substantial depth. No content from Peter Attia, Rhonda Patrick, Chris Kresser, Life Extension or Lifespan.io is listed: none has published material on AHK-Cu, the only related copper-peptide content on these platforms is members-only, and Life Extension’s 2014 scalp feature mentions the copper peptide in just two sentences. Because the Huberman episode does not discuss AHK-Cu by name, that item qualifies through the shared copper-tripeptide mechanism.
Grokipedia
-
AI-written encyclopedia entry on the AHK peptide and its copper complex, covering structure, synthesis and the 2007 follicle findings; useful for nomenclature, though it rests on the same single study.
Examine
No Examine article on AHK-Cu exists.
ConsumerLab
No ConsumerLab article on AHK-Cu exists.
Systematic Reviews
No systematic reviews or meta-analyses for AHK-Cu were found on PubMed as of October 25, 2026.
Neither the claimed hair and skin effects nor the copper-related risks of AHK-Cu are represented by a systematic review.
Mechanism of Action
AHK-Cu is the tripeptide alanyl-histidyl-lysine chelated (held in a ring-like grip) to a copper(II) ion through the alanine amino group, the histidine side chain and a backbone nitrogen, as in GHK-Cu. At about 418 Da (daltons, a unit of molecular mass) it is below the roughly 500 Da limit for skin penetration (Bos 2000).
- Follicle signaling: In cultured human follicles, AHK-Cu increased dermal papilla cell proliferation, raised the ratio of Bcl-2 (a protein that blocks programmed cell death) to Bax (a protein that promotes it), and lowered cleaved caspase-3 (an enzyme executing programmed cell death) and cleaved PARP (poly(ADP-ribose) polymerase, a DNA-repair enzyme cut during cell death) (Pyo 2007), changes proposed to prolong anagen (the active growth phase).
- Blood supply (analog data): GHK-Cu raised irradiated human skin fibroblast output of VEGF (vascular endothelial growth factor, a signal for new blood vessels) and bFGF (basic fibroblast growth factor, a repair signal) (Pollard 2005); VEGF-driven vessel growth enlarged hair follicles in mice (Yano 2001).
- Competing explanation: The effect may come from copper rather than the peptide: peptide-free copper-doped gels also increased hair follicle numbers in animal skin (Yergeshov 2022). No data show AHK-Cu acting on the androgen pathway behind pattern hair loss.
- Pharmacology: Half-life, tissue distribution and metabolism are unstudied in humans, and no receptor selectivity is known. As an unmodified tripeptide it is expected to be cut by peptidases (protein-cutting enzymes), not cytochrome P450 (CYP) liver enzymes; released copper joins the body’s pool, cleared through bile.
Historical Context & Evolution
AHK-Cu was designed as a synthetic analog of GHK, the copper-binding tripeptide that Loren Pickart isolated from human plasma in the early 1970s and whose blood levels decline with age, as summarized in his later review (Pickart 2018). Its original intended use was as a hair-growth drug candidate. A 1994 patent filing by ProCyte Corporation described AHK-Cu solutions that, injected into or applied to mouse skin, triggered hair growth, and that preserved hair around injection sites in young animals given the chemotherapy drug cytarabine (ProCyte patent US5538945). These are company data, reported in a patent by a firm with a commercial interest.
In 2007, a Seoul National University group reported that AHK-Cu lengthened human scalp follicles kept alive in culture (Pyo 2007), the finding on which most current interest rests. The compound then entered cosmetics as “copper tripeptide-3” in scalp serums, chosen for health optimization because it promised a non-hormonal way to support hair.
During the 2020s it was drawn into the online peptide trade, sold in vials labeled for research use and injected by some users together with GHK-Cu, part of a gray-market trend that a recent clinical review documents for GHK-Cu and other unapproved peptides (Mendias 2026). What changed was availability and route of use, not the evidence: no human trial followed, and the 2007 observations have been neither replicated nor contradicted. Their standing remains that of an untested laboratory lead.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: no human clinical trial of AHK-Cu exists, and the only human trials of a related copper peptide tested a different compound.
Medium 🟩 🟩
No benefit reaches Medium: there is no single controlled human trial and no observational study with a comparison group for AHK-Cu.
Low 🟩
Skin Repair and Wrinkle Appearance ⚠️ Conflicted ⭕️ Not Central to Health & Longevity
Evidence is indirect: trials tested GHK-Cu, not AHK-Cu. A 2026 systematic review found two RCTs (randomized controlled trials): wrinkles fell versus control in aging skin (Mokhtar 2026), but not in 13 patients healing from laser resurfacing, a different setting (Miller 2006). This bears on appearance. Net, support is thin.
Magnitude: In a randomized double-blind GHK-Cu trial in 40 women, wrinkle volume was 55.8% lower (P < .001; P, the probability of a chance difference) and wrinkle depth 32.8% lower (P = .012) than with vehicle serum (the same serum without GHK-Cu) after 8 weeks (Badenhorst 2016). In the 13-patient laser trial, blinded ratings did not differ between groups; only patient-rated skin quality favored GHK-Cu (P = .04) (Miller 2006).
Scalp Hair Follicle Growth ⭕️ Not Central to Health & Longevity
Evidence is indirect: the only human trial tested a GHK peptide complexed with 5-aminolevulinic acid, not AHK-Cu (Lee 2016). AHK-Cu itself lengthened cultured human follicles (Pyo 2007) and regrew mouse hair in company studies (ProCyte patent US5538945). It bears on hair density, not lifespan.
Magnitude: In a placebo-controlled trial in 45 men with pattern hair loss, hair count rose by 71.5 (50 mg/mL) and 52.6 (100 mg/mL) versus 9.6 with placebo over 6 months; the 50 mg/mL group’s change ratio differed significantly from placebo (2.38 vs 1.21, P < .05), the 100 mg/mL group’s change was not compared between groups, and hair length and thickness did not differ (Lee 2016).
Speculative 🟨
Systemic Tissue Repair and Longevity
Whole-body repair claims for injected AHK-Cu are extrapolated from GHK-Cu gene-expression and animal data summarized in a review (Pickart 2018). No AHK-Cu study has measured systemic or lifespan outcomes; the basis is mechanistic only.
Benefit-Modifying Factors
- Genetic polymorphisms: No AHK-Cu pharmacogenetic data exist. Pattern hair loss is driven largely by inherited sensitivity to DHT (dihydrotestosterone, the androgen that shrinks scalp follicles); because AHK-Cu has no known action on this pathway, strongly androgen-driven loss may respond less (inferred).
- Baseline biomarkers: Copper status could plausibly modify response, with copper-deficient tissue gaining more than copper-replete tissue; this is untested. The degree of follicle shrinkage at baseline decides whether viable follicles remain to stimulate.
- Sex: No sex-specific data exist. Female pattern hair loss is less androgen-dependent than male pattern loss, so a non-hormonal follicle stimulant could be relatively more relevant in women; this is inferred, not studied.
- Pre-existing conditions: Scarring alopecias (hair loss that destroys follicles) leave nothing to stimulate. Telogen effluvium (shedding triggered by illness or stress) often resolves on its own, which can be mistaken for a product effect.
- Age: Blood GHK levels fall with age (review: Pickart 2018), the main rationale for copper peptides in older adults, but no study has tested whether age changes the response to AHK-Cu. Older scalps also hold fewer active follicles.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: no trial of AHK-Cu in humans has recorded adverse events from which a replicated harm could emerge.
Medium 🟥 🟥
No risk reaches Medium: there is no single controlled human study and no observational study with a comparison group for AHK-Cu.
Low 🟥
Copper Excess With Injection or Overdosing
Evidence is indirect: human data concern ingested soluble copper salts, not peptide-bound copper. A toxicology review reports that high intakes cause acute gastrointestinal symptoms and, uncommonly, liver toxicity with repeated exposure in susceptible people (Taylor 2020). Mis-dosed injectable vials are the plausible route to excess.
Magnitude: The review derives a protective oral dose of 0.04 mg copper per kg body weight per day, with liver toxicity confined mainly to genetically susceptible people and excessive supplement users; the literature reports no outcome figure for peptide-bound copper and has no comparison group for it (Taylor 2020).
Speculative 🟨
Contaminated or Mislabeled Gray-Market Injectables
Test purchases of another online-sold peptide found endotoxin (bacterial toxin) in every vial and purity far below labeled values (Ashraf 2024). No AHK-Cu data exist; the basis is one isolated report on another product.
Skin Irritation From Unbound Copper
In a skin-cell model, copper salts raised irritation markers while GHK-Cu did not (Li 2016). Poorly complexed AHK-Cu products could carry free copper; only laboratory data exist.
Support of Blood-Vessel Growth in Existing Tumors
Copper is needed for angiogenesis (new blood-vessel growth), and copper lowering has been studied against cancer, as a review describes (Brewer 2014). Whether AHK-Cu feeds tumors is unknown; the basis is mechanistic only.
Immune Reactions to Injected Peptide
Injected synthetic peptides and their impurities can provoke hypersensitivity or injection-site reactions. No AHK-Cu reports exist; the concern is mechanistic and drawn from experience with other injected peptides.
Risk-Modifying Factors
- Genetic polymorphisms: ATP7B (gene for the pump that moves excess copper into bile) mutations cause Wilson disease (inherited copper overload). Carriers of one variant may clear extra copper less efficiently (inferred); injected AHK-Cu would carry the most risk.
- Baseline biomarkers: Elevated serum copper, low ceruloplasmin (the main copper-carrying blood protein) or raised liver enzymes before starting point to reduced copper tolerance or undiagnosed liver disease.
- Sex: No sex-specific risk data exist. Estrogen-containing contraceptives and pregnancy raise serum copper and ceruloplasmin, which complicates interpretation of monitoring; pregnancy also lacks any safety data.
- Pre-existing conditions: Cholestatic liver disease (impaired bile flow) reduces copper excretion; a cancer history raises the theoretical blood-vessel growth concern; scalp eczema or psoriasis raises irritation risk with topical use.
- Age: Older adults have thinner, drier skin prone to irritation and are more likely to have liver disease or undiagnosed cancer; no age-specific data exist.
Key Interactions & Contraindications
Documented interactions:
- None identified
Theoretical interactions (inferred from mechanism, not studied in humans):
- Copper chelators (penicillamine, trientine, tetrathiomolybdate): Added copper opposes their copper-lowering purpose in Wilson disease or cancer protocols (review: Brewer 2014), reducing their effect; inferred from opposing actions on body copper. Mitigation: any combined use is coordinated with the prescribing physician.
- Copper supplements and other copper peptides (copper bisglycinate, copper-containing multivitamins, GHK-Cu): Additive copper load raises the chance of copper excess; inferred from shared copper content. Mitigation: totaling all copper sources and checking serum copper.
- Vitamin C serums and acid exfoliants (L-ascorbic acid, glycolic acid, salicylic acid): Ascorbate reduces copper(II) and low pH loosens copper-peptide binding, degrading the product and raising irritation; inferred from copper redox chemistry. Mitigation: application at different times of day.
- Topical retinoids (vitamin A-derived skin drugs; tretinoin, adapalene): Additive scalp or skin irritation; inferred from overlapping irritant potential. Mitigation: alternating nights or separate application sites.
- Over-the-counter minoxidil and prescription finasteride: Different hair-growth mechanisms may add; no interaction studied, but combined use blurs attribution and minoxidil vehicles add irritation. Mitigation: introducing one agent at a time, each documented with standardized photographs.
- Angiogenic peptide combinations (BPC-157, TB-500; unapproved repair peptides): Additive pro-angiogenic signaling, relevant to people with cancer history; inferred from shared effects on blood-vessel growth. Mitigation: no combined use where cancer risk is elevated.
- Microneedling and laser resurfacing: Breaching the skin barrier increases penetration and irritation; inferred from barrier physics (Bos 2000). Mitigation: sterile product only, applied after the barrier has closed.
Populations who should avoid AHK-Cu:
- Wilson disease (any stage, including treated): Practice guidance advises limiting copper intake (Schilsky 2022); the issuing hepatology society’s members derive no direct revenue from that advice.
- Pregnancy and breastfeeding: Inferred from systemic copper delivery by injection and the absence of any reproductive safety data; no human data.
- Active cancer or cancer under treatment: Inferred from copper’s role in tumor blood-vessel growth (review: Brewer 2014); no human data.
- Cholestatic liver disease (primary biliary cholangitis, primary sclerosing cholangitis; autoimmune bile-duct diseases): Inferred from bile being the main route of copper excretion; no human data.
- Known copper contact allergy: Inferred from the copper content of the complex; no AHK-Cu data.
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Topical rather than injected use: Limits systemic copper exposure and avoids injection contamination; the patent specifies topical compositions of 0.1–5% w/w (weight per weight) (ProCyte patent US5538945).
- Lot-specific testing: Requiring purity by HPLC (high-performance liquid chromatography) of at least 98%, mass-spectrometry identity, endotoxin and sterility results addresses failures documented in gray-market vials (Ashraf 2024); mitigates contamination.
- Total copper cap: Total copper from diet, supplements and topical peptides is kept within the oral reference dose of 0.04 mg/kg/day (Taylor 2020); no injected-copper limit exists. Each milligram of AHK-Cu carries roughly 0.15 mg copper. Mitigates copper excess.
- Patch testing: Application to a 2 cm area of the inner forearm for 48 hours before scalp use, stopping at redness or itching. Mitigates skin irritation from unbound copper.
- Laboratory checks for injected use: Serum copper, ceruloplasmin and ALT (alanine aminotransferase, a liver enzyme) at baseline and 8–12 weeks, stopping if ALT exceeds 3× the upper limit of normal. Mitigates copper excess and liver injury.
- Cancer screening: Age-appropriate cancer screening kept current, and no use during active cancer. Mitigates the theoretical tumor blood-vessel growth risk.
- Sterile technique: Single-use needles, alcohol swabs and bacteriostatic water, with reconstituted vials discarded after 30 days. Mitigates injection-site infection and immune reactions to degraded product.
Therapeutic Protocol
Doses below are cited to their source; other parameters without a citation (timing, cycling, titration steps) reflect common practice.
- Topical scalp serum (most common approach): About 200–500 ppm (parts per million), once daily, per a vendor-linked dosing site (PeptideDosage AHK-Cu protocol); the patent tested 0.1% and 0.5% w/w twice daily in mice (ProCyte patent US5538945).
- Topical serum in a registered trial: Roughly 1–3 mg/mL applied to defined skin sites as part of a five-peptide serum that includes AHK-Cu (NCT07888595).
- Subcutaneous injection (no established protocol): A dosing site lists 250, 350, then 500 mcg daily as an educational syringe chart, stating real-world use is topical and no validated injectable protocol exists (PeptideDosage AHK-Cu protocol); no human safety data exist.
- Laboratory effective concentration: 10⁻¹²–10⁻⁹ M (trillionths to billionths of a mole per liter) in cultured follicles (Pyo 2007), far below cosmetic concentrations; the optimal human dose is unknown.
- Who popularized it: No clinic or named practitioner champions AHK-Cu; use spread through cosmetic ingredient suppliers and online peptide vendors, building on the copper-peptide work of Loren Pickart, whose company sells GHK-Cu products (Pickart 2018).
- Time of day: Evening application to a clean, dry scalp gives hours of contact; no data favor any time of day.
- Half-life: Not established in humans; as an unmodified tripeptide it is expected to be broken down within minutes to hours, so effects depend on repeated local exposure.
- Single or split doses: Topical serums are applied once daily; the mouse work used twice-daily application; the dosing site’s educational injection chart assumes once daily. No data compare schedules.
- Genetic polymorphisms: No pharmacogenetic guidance exists; people with known ATP7B variants or a family history of Wilson disease are poor candidates for injected use.
- Sex: No sex-specific dosing exists; injected copper exposure lacks reproductive safety data, which is most relevant for women planning pregnancy.
- Age: No age-specific dosing exists; older adults with fragile skin often start at the low end of topical concentrations and apply every other day.
- Baseline biomarkers: Normal serum copper, ceruloplasmin and liver enzymes are a common prerequisite for injected use; abnormal values argue against starting.
- Pre-existing conditions: Scalp dermatitis is usually treated before starting topical use; liver disease or active cancer argues against injected use.
Discontinuation & Cycling
- Lifelong or short-term: Not designed as lifelong; response is judged after 3–6 months of hair-cycle time. Continued use is common if benefit appears, since follicle stimulants generally lose effect once stopped (inferred).
- Withdrawal effects: None are known. Any hair gains may regress over months as follicles return to their prior cycle.
- Tapering: Not needed; there is no known physiological dependence, so AHK-Cu can be stopped at once.
- Cycling: No evidence shows cycling preserves efficacy. Some people who inject cycle 8–12 weeks on and 4 weeks off to limit cumulative copper exposure; this is unvalidated common practice.
Sourcing and Quality
- Formulation types: Cosmetic scalp serums list the ingredient as copper tripeptide-3, whereas lyophilized (freeze-dried) vials are labeled “research use only” and are not manufactured under GMP (good manufacturing practice) for human use.
- What to look for: A lot-specific certificate of analysis from an independent laboratory showing HPLC purity, mass-spectrometry identity, endotoxin, sterility and heavy-metal results, rather than a vendor’s own unverified sheet.
- Color as a quick check: Genuine copper-peptide solutions are blue to violet; the patent describes AHK-Cu at 10 mg/mL as dark blue-purple (ProCyte patent US5538945). A colorless product suggests missing copper.
- Copper-to-peptide ratio: The patent prepared peptide-to-copper ratios of 1:1 to 2:1; excess unbound copper raises irritation potential (Li 2016).
- Reputable brands and pharmacies: No independent tester has evaluated AHK-Cu products, so no brand stands out. Under U.S. Food and Drug Administration (FDA) rules, compounding pharmacies could use it only after placement on the section 503A bulks list (FDA 503A bulks page).
- Storage: Copper peptides oxidize with light and air; powder is typically stored frozen and serums cool and dark, and discolored or cloudy product indicates degradation.
Practical Considerations
- Time to effect: In mice, injected AHK-Cu produced visible hair growth within 14–20 days (ProCyte patent US5538945); human hair-cycle changes generally need 3–6 months to become visible, and no human timing data exist.
- Common pitfalls: Treating GHK-Cu evidence as AHK-Cu evidence, mixing serums with vitamin C, judging results after a few weeks, injecting research-grade vials, and combining several copper sources without counting total copper.
- Regulatory status: AHK-Cu is not FDA-approved and has no USP (United States Pharmacopeia) monograph, so compounding would require placement on FDA’s 503A bulks list (FDA 503A bulks page). Retail sale is as a cosmetic ingredient; injectable vials carry “research use only” labels.
- Cost and incentives: AHK-Cu is inexpensive. Insurers do not reimburse cosmetic hair treatment, so no payer incentive shapes this evidence; the expired ProCyte patent (ProCyte patent US5538945) leaves little commercial incentive to fund human trials.
Interaction with Foundational Habits
- Sleep: None known. No mechanism links AHK-Cu to sleep, and evening scalp application does not affect sleep; poor sleep can worsen shedding independently.
- Nutrition: Indirect. Copper-rich foods (shellfish, organ meats, nuts, cocoa) add to total copper load; high-dose zinc supplements lower copper status. Adequate protein and iron support hair independently, and deficiencies can mask any AHK-Cu effect.
- Exercise: None known. Exercise neither blunts nor enhances any known AHK-Cu effect; heavy sweating can dilute a freshly applied serum, so it is commonly applied after the post-workout shower.
- Stress management: Indirect. Chronic stress can trigger telogen effluvium, which AHK-Cu does not address; managing stress removes a cause of shedding that would otherwise confound judging the peptide’s effect.
Monitoring Protocol & Defining Success
Before starting, baseline testing establishes copper status and liver health, and standardized scalp photographs or a phototrichogram (a magnified hair count of a marked scalp area) record hair density. These baselines matter most for anyone planning injections, where copper enters the bloodstream directly and product quality is uncertain. Low ceruloplasmin or elevated liver enzymes at baseline argue against starting.
Ongoing monitoring follows this cadence: for injected use, laboratory tests at 8–12 weeks, then every 6 months while use continues; for topical use, repeat laboratory tests only if total copper intake is high. Hair photographs and counts are repeated at 3 and 6 months, since earlier changes are hard to distinguish from normal shedding. Success is a measurable rise in hair count or thickness from the person’s own baseline without any change in safety markers.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Serum copper | 70–140 µg/dL (standard reference range) | Safety check: rising values signal copper excess | No fasting needed; laboratory ranges vary; estrogen therapy and pregnancy raise values; best paired with ceruloplasmin |
| Ceruloplasmin | 20–40 mg/dL (standard reference range) | Safety check: low values suggest Wilson disease, ruling out use | Rises with inflammation and estrogen; morning draw with serum copper |
| ALT | 7–56 U/L (standard reference range) | Safety check: elevation stops or changes use | Alanine aminotransferase, a liver enzyme; hard exercise in the prior 48 hours can raise values; use stops above 3× the upper limit of normal (common practice); best paired with AST (aspartate aminotransferase) |
| Hair count/density (phototrichogram) | No established target; track change from own baseline | Marker expected to change if AHK-Cu works | Same scalp site, lighting and magnification each time; compared at 3 and 6 months |
Qualitative markers:
- Shedding volume during washing and brushing
- Scalp redness, itching or burning after application
- Hair thickness, texture and visible scalp coverage in photographs
- Skin texture and firmness where serum is applied
- Injection-site redness, swelling or lumps
Emerging Research
- Topical aging-protective peptide serum trial (NCT07888595): Early phase 1, 48 participants, enrolling by invitation, completion 2028; a serum containing AHK-Cu and four other peptides is compared with untreated skin on transcriptomic biological age (age estimated from gene-activity patterns). Positive: first human skin data involving AHK-Cu, though confounded by co-ingredients. Null: weakens skin-rejuvenation claims.
- GHK-Cu wound-healing trial (NCT07437586): Phase 2, 60 healthy adults, vehicle-controlled split-wound design (two wounds per person, one given inactive gel), primary endpoint time to complete re-epithelialization (skin closure); recruiting, completion 2028. Positive: strengthens the analog rationale for copper-peptide skin repair. Null: weakens extrapolation from GHK-Cu to AHK-Cu.
- Replication of follicle findings: The 2007 follicle results (Pyo 2007) remain unreplicated, and a 2026 review notes that peptide hair studies rarely justify their doses (Fan 2026). An independent replication or controlled scalp trial would move the hair item up or down.
- Copper and tumor biology: Research on copper lowering as an anticancer strategy, summarized in a review (Brewer 2014) could sharpen or dispel the theoretical concern that extra copper supports tumor blood-vessel growth.
- Is the peptide or the copper active? Peptide-free copper materials also stimulated follicles in animals (Yergeshov 2022); head-to-head studies of AHK-Cu, GHK-Cu and simple copper salts could show whether AHK-Cu adds anything specific.
Conclusion
AHK-Cu is a synthetic copper-carrying peptide built to resemble a natural copper peptide in human blood. It is used mostly as a scalp serum and, increasingly, as a self-injected product bought online, by people hoping to keep their hair, improve their skin and support tissue repair as they age.
The evidence is thin. Its main support is laboratory work in which it lengthened human hair follicles kept alive outside the body, plus older company animal studies. No study has tested it in people for any outcome. Skin benefits rest on trials of its natural relative, and those trials disagree. Claims of whole-body repair or longer life are extrapolations from that relative and from animal work.
The main risks follow from what is known about copper and about unregulated products: too much copper from mis-dosed injections, contamination of vials sold for research use, skin irritation from poorly made serums, and a theoretical concern about feeding blood-vessel growth in existing tumors. People with inherited copper-storage disease face the clearest hazard.
Much of the background research comes from a scientist who sells copper-peptide products and from a company patent, and practical dosing comes from vendor websites, so the evidence base carries commercial interests on the side of the product. For a risk-aware person, AHK-Cu is a low-cost, plausible but unproven hair and skin experiment, with uncertainty that is greatest for injected use.